Robert E Michler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5754623/publications.pdf

Version: 2024-02-01

59 papers 6,479 citations

304602 22 h-index 51 g-index

62 all docs 62 docs citations

times ranked

62

5622 citing authors

#	Article	IF	CITATIONS
1	Human cardiac stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14068-14073.	3.3	925
2	Mitral-Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. New England Journal of Medicine, 2014, 370, 23-32.	13.9	792
3	Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. New England Journal of Medicine, 2016, 374, 344-353.	13.9	752
4	Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction. New England Journal of Medicine, 2011, 364, 1617-1625.	13.9	734
5	Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. New England Journal of Medicine, 2016, 374, 1511-1520.	13.9	731
6	Coronary Bypass Surgery with or without Surgical Ventricular Reconstruction. New England Journal of Medicine, 2009, 360, 1705-1717.	13.9	652
7	Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation. New England Journal of Medicine, 2016, 374, 1932-1941.	13.9	403
8	Surgical Treatment of Moderate Ischemic Mitral Regurgitation. New England Journal of Medicine, 2014, 371, 2178-2188.	13.9	358
9	Identification of a coronary vascular progenitor cell in the human heart. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15885-15890.	3.3	188
10	Insights from the STICH trial: Change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 1139-1145.e6.	0.4	157
11	The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer, 1998, 82, 1978-1987.	2.0	126
12	Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction. Circulation, 2015, 132, 720-730.	1.6	72
13	Impact of Left Ventricular to Mitral Valve Ring Mismatch on Recurrent Ischemic Mitral Regurgitation After Ring Annuloplasty. Circulation, 2016, 134, 1247-1256.	1.6	58
14	Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. JACC: Cardiovascular Imaging, 2015, 8, 1121-1129.	2.3	51
15	To STICH or not to STICH: We know the answer, but do we understand the question?. Journal of Thoracic and Cardiovascular Surgery, 2005, 129, 246-249.	0.4	42
16	Recommendations of the National Heart, Lung, and Blood Institute Working Group on Future Direction in Cardiac Surgery. Circulation, 2005, 111, 3007-3013.	1.6	40
17	Progenitor Cells From the Explanted Heart Generate Immunocompatible Myocardium Within the Transplanted Donor Heart. Circulation Research, 2009, 105, 1128-1140.	2.0	33
18	The current status of stem cell therapy in ischemic heart disease. Journal of Cardiac Surgery, 2018, 33, 520-531.	0.3	33

#	Article	IF	CITATIONS
19	Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 149-159.	1.4	29
20	Treatment options for ischemic mitral regurgitation: A meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 607-622.e14.	0.4	29
21	The Effects of Self-Hypnosis on Quality of Life Following Coronary Artery Bypass Surgery: Preliminary Results of a Prospective, Randomized Trial. Journal of Alternative and Complementary Medicine, 1995, 1, 285-290.	2.1	28
22	Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization. Circulation: Heart Failure, 2018, 11, e005531.	1.6	26
23	Stem Cell Therapy for Heart Failure. Methodist DeBakey Cardiovascular Journal, 2021, 9, 187.	0.5	25
24	Management Strategies for Pulmonary Vein Thrombosis Following Single Lung Transplantation. Journal of Cardiac Surgery, 1995, 10, 169-178.	0.3	22
25	The Choice of Treatment in Ischemic Mitral Regurgitation With Reduced Left Ventricular Function. Annals of Thoracic Surgery, 2019, 108, 1901-1912.	0.7	20
26	The STICH trial: evidenceâ€based conclusions. European Journal of Heart Failure, 2010, 12, 1028-1030.	2.9	19
27	Myocyte repolarization modulates myocardial function in aging dogs. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H873-H890.	1.5	17
28	Surgical aspects of congestive heart failure. Heart Failure Reviews, 2006, 11, 171-192.	1.7	12
29	Surgical management of moderate ischemic mitral regurgitation at the time of coronary artery bypass grafting remains controversial. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1498-1500.	0.4	11
30	De Novo Renal Failure and Clinical Outcomes of Patients With Critical Coronavirus Disease 2019. Critical Care Medicine, 2021, 49, e161-e169.	0.4	11
31	Reflections on the coronavirus disease 2019 (COVID-19) epidemic: TheÂfirst 30 days in one of New York's largest academic departments ofÂsurgery. Surgery, 2020, 168, 212-214.	1.0	9
32	Current and Future Status of Stem Cell Therapy in Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 614-627.	0.4	8
33	Learning From Controversy: Management of Severe Ischemic Mitral Regurgitation at the Time of CABG. Annals of Thoracic Surgery, 2019, 108, 321-323.	0.7	8
34	The outcome of surgical management of type A aortic dissection. Asian Cardiovascular and Thoracic Annals, 2014, 22, 687-693.	0.2	7
35	Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial. Circulation, 2022, 145, 819-828.	1.6	7
36	A Comparison of Inflammatory Responses Between Robotically Enhanced Coronary Artery Bypass Grafting and Conventional Coronary Artery Bypass Grafting: Implications for Hybrid Revascularization. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 251-258.	0.6	6

#	Article	IF	Citations
37	A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 950-957.	0.4	5
38	Hybrid Arch Debranching and Proximal Endograft Extension to Repair a Type I Endoleak after Endovascular Thoracic Aneurysm Repair. Annals of Vascular Surgery, 2014, 28, 740.e7-740.e12.	0.4	4
39	Accessory Liver in the Right Atrium: A Rare Cause of Syncope. Annals of Thoracic Surgery, 2016, 102, e229-e231.	0.7	4
40	Immature Host for Xenotransplantation. World Journal of Surgery, 1997, 21, 924-931.	0.8	3
41	Differential Impact of Mitral Valve Repair on Outcome of Coronary Artery Bypass Grafting with or without Surgical Ventricular Reconstruction in the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. Structural Heart, 2019, 3, 302-308.	0.2	3
42	A Case Series of a Hybrid Approach to Aortic Arch Disease. Heart Surgery Forum, 2013, 16, 225.	0.2	3
43	Risk Factors Predicting the Postoperative Outcome in 134 Patients with Active Endocarditis. Heart Surgery Forum, 2014, 17, 35.	0.2	3
44	Long-term results of surgical ventricular reconstruction and comparison with the Surgical Treatment for Ischemic Heart Failure trial. Journal of Thoracic and Cardiovascular Surgery, 2024, 167, 713-722.e7.	0.4	3
45	How Informed is "Informed Consent―for Robotic Cardiothoracic Surgery?. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2009, 4, 307-310.	0.4	2
46	Surgical Options for the Management of Ischemic Cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 518-532.	0.4	1
47	Response to Letter Regarding Article "lnositol 1,4,5-Trisphosphate Receptors and Human Left Ventricular Myocytes― Circulation, 2014, 129, e510-1.	1.6	1
48	Do the "eyes―have it? Lobbying for magnetic resonance imaging to guide transcatheter aortic valve deployment. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 1072-1073.	0.4	1
49	Identifying patients who benefit from restrictive annuloplasty in ischemic mitral regurgitation: An elusive yet essential quest! Toward a patient-tailored approach. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 906-908.	0.4	1
50	Impact of Intubation Time on Survival following Coronary Artery Bypass Grafting: Insights from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 1256-1263.	0.6	1
51	Abstract 577: Origin and Therapeutic Efficacy of Human Cardiac Progenitor Cells. Circulation, 2007, 116, .	1.6	1
52	You Be the Judge: Is Long-Term Benefit Worth the Early Risk?. Seminars in Thoracic and Cardiovascular Surgery, 2014, 26, 306-309.	0.4	0
53	The role of stem cells in treating coronary artery disease in 2018. Indian Journal of Thoracic and Cardiovascular Surgery, 2018, 34, 340-348.	0.2	0
54	Aortic recoarctation and pseudoaneurysm five decades after repair. Journal of Cardiac Surgery, 2019, 34, 1374-1376.	0.3	0

#	Article	IF	CITATIONS
55	Reply. Annals of Thoracic Surgery, 2020, 110, 345.	0.7	0
56	Restoring ventricular restoration: A call to reâ€evaluate a surgical therapy considered ineffective. Journal of Cardiac Surgery, 2021, 36, 693-695.	0.3	0
57	Abstract 3422: Asymmetric Division of Human Cardiac Progenitor Cells Involves Immortal DNA Strand Cosegregation. Circulation, 2008, 118, .	1.6	O
58	Asymmetric Sternotomy and Sternal Wound Complications: Assessment Using 3-Dimensional Computed Tomography Reconstruction. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2015, 10, 52-56.	0.4	0
59	Wisdom of experience or faculty of reason: Ischemic mitral regurgitation trials—Cardiothoracic Surgical Trials Network and beyond. JTCVS Open, 2020, 1, 12-16.	0.2	0